| 3.09 -0.04 (-1.28%) | 09-14 14:28 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.89 | 1-year : | 4.25 |
| Resists | First : | 3.33 | Second : | 3.64 |
| Pivot price | 3.14 |
|||
| Supports | First : | 2.82 | Second : | 2.35 |
| MAs | MA(5) : | 3.16 |
MA(20) : | 3.16 |
| MA(100) : | 3.47 |
MA(250) : | 4.2  |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 31.8 |
D(3) : | 37.8 |
| RSI | RSI(14): 48.9 |
|||
| 52-week | High : | 12.14 | Low : | 2.76 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ EVAX ] has closed above bottom band by 43.4%. Bollinger Bands are 20% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.2 - 3.22 | 3.22 - 3.23 |
| Low: | 3.07 - 3.08 | 3.08 - 3.09 |
| Close: | 3.1 - 3.13 | 3.13 - 3.15 |
Evaxion Biotech A/S is a clinical-stage biotechnology firm dedicated to creating artificial intelligence-driven immunotherapies. Its innovative pipeline targets cancers, bacterial infections, and viral diseases. The company's oncology portfolio features several promising candidates: EVX-01, a leading cancer immunotherapy currently in Phase IIb clinical trials for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy undergoing Phase IIa trials for adjuvant melanoma; and EVX-03, another DNA-based immunotherapy in development for a range of cancers. Beyond oncology, Evaxion is advancing three pre-clinical vaccine candidates—EVX-B1, EVX-B2, and EVX-V1—aimed at combating various bacterial and viral pathogens. Founded in 2008, Evaxion Biotech A/S is headquartered in Hørsholm, Denmark.
Tue, 28 Jul 2026
Evaxion Biotech A/S (EVAX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - tradingkey.com
Mon, 27 Jul 2026
Evaxion Biotech A/S (EVAX) Dividends & Stock Splits: Historical Payouts and Event Timeline - tradingkey.com
Tue, 26 May 2026
EVAX - Finviz
Tue, 17 Feb 2026
EVAX Should I Buy - Intellectia AI
Thu, 11 Sep 2025
Evaxion A/S (EVAX) Stock Price, News & Analysis - MarketBeat
Mon, 26 May 2025
Evaxion: Progress Unrecognized By Market And A Catalyst-Full 2025 (NASDAQ:EVAX) - Seeking Alpha
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 9 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 17.4 (%) |
| Held by Institutions | 10 (%) |
| Shares Short | 21 (K) |
| Shares Short P.Month | 21 (K) |
| EPS | -0.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.13 |
| Profit Margin | -115.6 % |
| Operating Margin | -116.1 % |
| Return on Assets (ttm) | -26 % |
| Return on Equity (ttm) | -109.9 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0.83 |
| Sales Per Share | 0.83 |
| EBITDA (p.s.) | -0.93 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -7 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -6.24 |
| PEG Ratio | 0 |
| Price to Book value | 2.73 |
| Price to Sales | 3.75 |
| Price to Cash Flow | -3.93 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|